explore -WSS

explore

author：fashion 2025-09-06 04:26:35 - browse：71743

gantenerumab Alzheimer's disease Roche — Sebastien Bozon/AFP via Getty Images

LONDON — Roche on Thursday said its recently acquired experimental obesity medication helped people lose a significant amount of weight in an early trial, sending its shares up in early trading.

The drug, a once-weekly injection known as CT-388, resulted in an average placebo-adjusted weight loss of 18.8% after 24 weeks, the company said. The study was a Phase 1 trial, though it was placebo-controlled.

The reaction to such an early result — Roche shares were up roughly 4% early Thursday — is a signal both of the stakes of the obesity medication race and the keen interest investors have in the field.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Alkermes shareholders re
Next article： HHS leader on health, climate change and biopharma emissions

leisure time

explore

WSS

Study: Pain burden is higher in Black NFL players than white ones

CEOs share strategies for surviving biotech slump

How climate

UnitedHealth’s board chair also owns a personal investment firm

Retired US general questions alleged Putin, Prigozhin meeting

Will Ozempic

entertainment

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

hotspot

Malaria cases in Florida and Texas: Here’s what you need to know

CEOs share strategies for surviving biotech slump

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

NIH fellows want a pay raise. Will that mean less money for grants?

At least 13 dead in Texas as scorching temps continue

NIH fellows want a pay raise. Will that mean less money for grants?

Medicare proposal to cover medical devices draws a mixed reaction

New research casts further doubt on a common procedure used with IVF

As demand for Covid shots wanes, Moderna seeks its next success

It's time to get medical device identifiers over the finish line

entertainment

Pharmacists can make shortage drugs, but at what cost?

Beam Therapeutics to lay off 20% of its staff, re

Studies point to risks of excluding people with obesity from drug trials

How climate

Why 40% Americans with Parkinson’s don’t see a neurologist

The explosion of genetic testing requires a new approach

leisure time

leisure time

explore

focus